Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

ModulEndoA3 · Identification of cellular regulators and pharmacological inhibitors of endophilin-A3 to modulate its endocytic functions

HORIZONStatus: SIGNED1 June 202431 May 2026EU funding €191,760Call HORIZON-MSCA-2023-PF-01

In addition to classical clathrin-mediated endocytosis, mammalian cells have clathrin-independent endocytic (CIE) mechanisms. Among others, the BAR domain proteins, that sense and induce membrane curvature, are key players in CIE. In particular, the BAR domain protein endophilin-A3 (endoA3) drives CIE of the cell adhesion molecules CD166, L1CAM, and DICAM, with implications in tumour progression and viral infection. The regulation, mechanism, and functional implications of this recently-identified endoA3-mediated CIE route remain poorly characterized. In this context, I propose an interdisciplinary project combining cell biology, chemical biology, and virology approaches to substantially advance our understanding of endoA3-mediated CIE. The first research goal is to identify cellular regulators (kinases, phosphoinositides) that modulate endoA3-mediated endocytosis. In parallel, this project aims at identifying small molecule inhibitors that selectively inhibit the endocytic functions of endoA3. Subsequently, the cellular regulators and pharmacological inhibitors identified in this project will be used in cells, to modulate endoA3-mediated endocytosis and study the impact on cellular functions. Emphasis will be put on cancer cell properties and endocytic viral particle entry. Together, this project will generate high-quality fundamental knowledge on the mechanism and function of endoA3-mediated CIE. Moreover, the identification of modulators of endoA3 endocytic functions will provide valuable biological tools for the study of this recently-identified CIE route in physiology and pathology. Lastly, the identification of selective pharmacological inhibitors may pave the way towards the development of innovative antiviral and anti-cancer therapeutics targeted at unconventional endocytosis. This fellowship will be conducted in the laboratory of Prof. Henri-Francois Renard (UNamur, Belgium), who has been a pioneer in the identification of BAR-mediated endocytic routes.

Consortium · 2 organisations

coordinator

UNIVERSITE DE NAMUR

BE · €191,760

associatedPartner

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

FR

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.